+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the real-world impact, including safety and test accuracy, of the Galleri4 multi-cancer early detection blood test in Medicare beneficiaries aged 50 years and older. This multi-center prospective cohort study aims to represent the Medicare population and compares usual care with and without the addition of the Galleri test. The study focuses on screening for cancer and assessing how the test affects cancer diagnosis and management over time. Participants are grouped into two arms one receiving the Galleri test alongside usual care, and a second group receiving usual care alone without the Galleri test. The Galleri test involves blood collection and multi-cancer early detection testing with results returned to participants. The study is non-randomized and runs parallel for both groups, observing outcomes over up to three years. During the study, participants are monitored for the incidence of late-stage stage IV cancers. Researchers also track safety by counting invasive procedures prompted by test results, adherence to recommended cancer screenings, and healthcare resources used for cancer diagnostics. The total study duration includes up to three years of follow-up to observe outcomes, with no masking or blinding involved.

Age: 50Years +All GendersPhase Not Applicable
72 locations
T

Actively Recruiting

This research aims to find out if a therapist training program can help providers in early childhood settings use powered mobility devices with young children who have cerebral palsy classified at Gross Motor Function Classification System Levels IV-V. The study also evaluates whether the training is practical and helpful for therapists, families, and children, addressing gaps in access to powered mobility during a critical developmental period between 12 and 36 months. The study involves therapists receiving one to two days of in-person training on powered mobility implementation, followed by delivering a six-month intervention to child-caregiver pairs. Therapists conduct twelve biweekly home-based sessions using the Permobil Explorer Mini device, focusing on mobility opportunities, caregiver coaching, and integrating powered mobility into daily routines. The project includes surveys, interviews, and observations to understand barriers, co-design training, and test feasibility. Participants will complete assessments such as surveys, interviews, and video-recorded sessions to evaluate therapist knowledge, confidence, intervention fidelity, and caregiver feasibility of device use. Child outcomes like mobility, participation, and engagement are measured through caregiver reports and standardized assessments. The study spans from training through intervention and includes monitoring of acceptability, appropriateness, and feasibility over the six-month period.

Age: 12Months +All GendersPhase Not Applicable
3 locations
A

Actively Recruiting

Researchers are studying a new medicine called PF-08634404 to see how well it works in adults with metastatic colorectal cancer, which is cancer that has spread to other parts of the body. The study compares PF-08634404 combined with approved chemotherapy to an approved medicine called Bevacizumab combined with chemotherapy. The goal is to understand if the new medicine can improve outcomes for people whose cancer has spread or returned after previous treatments. Participants are randomly assigned to one of two treatment groups. One group receives PF-08634404 with chemotherapy, and the other group receives Bevacizumab with chemotherapy. All medicines are given through intravenous IV infusions at a clinical site. Treatment is given in cycles, and participants may continue treatment as long as it is helping and side effects are manageable. After treatment ends, participants return for a final visit around 30 to 37 days later. During the study, participants have regular visits for treatment, health checks, and tests. Follow-up continues every 12 weeks through phone, in-person visits, or health record reviews to monitor health status and any new treatments. Researchers will measure outcomes such as progression-free survival, overall survival, response rates, side effects, quality of life, and drug levels. The study is expected to last about 33 months per participant.

Age: 18Years +All GendersPhase 3
372 locations